Dublin, Ireland, 21 January 2022. biosyn Arzneimittel GmbH and Kora Healthcare have entered into an exclusive licensing agreement for the marketing and distribution of selenase®, a medicinal product for the treatment of proven selenium deficiency, in the United Kingdom.
As the marketing authorization holder, biosyn Arzneimittel GmbH had been working with a local distributor in the UK since 2006. From 1 February 2022, Kora Healthcare will take over the marketing authorization of selenase®, and will promote and distribute selenase® in the UK in the future.
Andreas Meyer, Managing Director of biosyn Arzneimittel GmbH, comments: «Due to the Brexit-related regulatory changes in the UK market, we have been intensively searching for a new partner to further expand our business in the UK. We are pleased to have found the ideal partner in Kora Healthcare. Through our joint collaboration, we aim to tackle selenium deficiency, which is an underestimated phenomenon in Europe, and particularly in the UK.»
Conor O’Daly, Chief Executive Officer of Kora Healthcare, adds: «This novel and first-to-market treatment for a selenium deficiency complements and strengthens our product portfolio in the UK. Our well-established UK infrastructure in a variety of existing clinical areas enables Kora to launch a market-ready product such as selenase® across the many applicable treatment pathways and regimens.»
About selenase®: selenase® (sodium selenite pentahydrate) is available as both an injectable and an oral solution, and is indicated for proven selenium deficiency that cannot be compensated for by food. selenase® has been used by healthcare professionals in the UK since 2006 in a variety of clinical settings where selenium deficiency may occur, including critical care, oncology, gynecology, and other areas. All selenase® products are available through any UK full-line wholesaler. selenase® is approved in 27 countries.
About Kora Healthcare
Kora Healthcare, a subsidiary of Immdal Limited, is a private healthcare and pharmaceutical company based in the Republic of Ireland. Kora Healthcare is a fully integrated healthcare company with core competencies in Research, Development & Innovation, Science & Medicine, Regulatory Affairs & Pharmacovigilance, Quality, Supply Chain, Marketing & Sales, Finance, and Customer Service. All divisions are managed from its headquarters in Dublin, Ireland. Kora Healthcare is strategically committed to continued growth and development, and is actively engaged in the licensing, partnering, development, and marketing of prescription medicines and consumer healthcare products. For more information, please visit www.korahealthcare.com.
About biosyn Arzneimittel GmbH
biosyn Arzneimittel GmbH is a pharma and biotech company headquartered in Fellbach. It specializes in trace elements, is a global market leader for high-dose selenium injections, as well as a developer and operating company of two worldwide unique GMP active substance productions. In the biotech area, it is also active with a glycoprotein, isolated from Megathura crenulata (also commonly known as the Giant Keyhole Limpet), a sea snail species found in California. 70 percent of the turnover is generated outside of Germany, spanning 27 countries around the globe.
With its activities in the areas of intensive care, intensive care, and endocrinology, as well as its manufactured products, biosyn is a partner for clinics and registered doctors in private practices working in the area of integrative medicine, conventional medicine, and naturopathy. Research and development are part of the staff’s responsibilities, as are the review of current medical and scientific literature and modern online marketing. The medium-sized family business attaches great importance to an open, committed and patient-oriented corporate culture.
